Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

Theres no cure for obstructive hypertrophic cardiomyopathy (oHCM) treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

Hypertrophic cardiomyopathy is the most common genetic heart disease, with prevalence estimates from one in 200 to one in 500. However, the true prevalence is poorly understood due to likely ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...

Add Yahoo as a preferred source to see more of our stories on Google. Living with obstructive hypertrophic cardiomyopathy (oHCM) means taking care to avoid things that could trigger or worsen your ...

If you or a loved one has recently been diagnosed with hypertrophic cardiomyopathy (HCM), you may have questions about what it means for your health and how to manage the condition. Understanding ...

The hearts of people with hypertrophic cardiomyopathy are thicker, and must beat more forcefully to pump out blood into the body. This can lead to a variety of symptoms, which may appear only ...

Hypertrophic cardiomyopathy (HCM) is a primary disease of cardiac muscle characterized by a thickening of the left ventricular wall and often predominantly affecting the interventricular septum. This ...